# Okyo Pharma (OKYO) — News

OKYO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/okyo/news

## Recent headlines

- [Okyo Pharma announces first patients enrolled in phase 3 pivotal trial of urcosimod for neuropathic corneal pain](https://www.ainvest.com/news/okyo-pharma-announces-patients-enrolled-phase-3-pivotal-trial-urcosimod-neuropathic-corneal-pain-2610) — AInvest Wire, Oct 6, 2026
  Okyo Pharma has announced first patients enrolled in phase 3 . This marks a significant milestone in the company’s clinical development program, as the trial is designed to evaluate the safety and efficacy of the investigational drug in a larger patient population. The phase 3 trial, known as the…
- [Okyo Pharma: Chairman Gabrielle Cerrone increased holdings in company, bringing total holding to 20.55% of issued share capital](https://www.ainvest.com/news/okyo-pharma-chairman-gabrielle-cerrone-increased-holdings-company-bringing-total-holding-20-55-issued-share-capital-2607) — AInvest Wire, Jul 22, 2026
  Gabrielle Cerrone, Chairman of Okyo Pharma, has increased her stake in the company, raising her total ownership to 20.55% of the issued share capital[1]. This move reflects a significant personal investment in the company’s future and aligns with Cerrone’s long-term commitment to Okyo Pharma’s…
- [Okyo Pharma - FDA agrees to single-dose Phase 3 study design and potential single-trial registration for urcosimod](https://www.ainvest.com/news/okyo-pharma-fda-agrees-single-dose-phase-3-study-design-potential-single-trial-registration-urcosimod-2607) — AInvest Wire, Jul 8, 2026
- [Okyo Pharma reports positive feedback from FDA Type D meeting and accelerates Urcosimod into global Phase 3 pivotal trial for neuropathic corneal pain](https://www.ainvest.com/news/okyo-pharma-reports-positive-feedback-fda-type-meeting-accelerates-urcosimod-global-phase-3-pivotal-trial-neuropathic-corneal-pain-2607) — AInvest Wire, Jul 8, 2026
- [Okyo Pharma Ltd: Okyo expands scientific advisory board with appointment of intl expert Marta Sacchetti, MD, PhD](https://www.ainvest.com/news/okyo-pharma-okyo-expands-scientific-advisory-board-appointment-intl-expert-marta-sacchetti-md-phd-2605) — AInvest Wire, May 19, 2026
  OKYO Pharma Ltd (NASDAQ:OKYO) has expanded its Scientific Advisory Board with the appointment of Marta Sacchetti, MD, PhD, an internationally recognized expert in ophthalmology and ocular immunology. Dr. Sacchetti brings extensive academic, clinical, and industry experience to the company, having…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).